Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III
8 days ago
- #immunotherapy
- #clinical trial
- #non-small-cell lung cancer
- Study evaluated 6-month nivolumab-ipilimumab (IO) therapy versus continuation in metastatic non-small-cell lung cancer (mNSCLC) patients with disease control.
- Randomized trial included 265 treatment-naïve mNSCLC patients; 71 were randomized to continuation (36) or experimental (stop and resume at progression, 35) arms.
- Median progression-free survival (PFS) was 18.7 months in the continuation arm vs. not reached in the experimental arm.
- Median overall survival (OS) was 55.5 months in the continuation arm vs. not reached in the experimental arm.
- 18-month OS rates were 80.6% (continuation) and 93.8% (experimental).
- Higher grade 3-5 treatment-related adverse events in the continuation arm (54.3% vs. 23.5%).
- Quality of life (QoL) deterioration was delayed in the experimental arm (median time NR vs. 15.5 months in continuation).
- Conclusion: Stopping IO at 6 months showed no survival harm, reduced severe adverse events, and delayed QoL deterioration.